Autopsy report · NCT03383146

A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04

“The Relamorelin program is being terminated solely based on a business decision.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 2 years 9 months before it stopped.
• 450 participants enrolled.
• Results were posted on the registry 1 year 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Allergan

Sponsor type

Industry

Conditions

Gastroparesis; Diabetes Mellitus

Interventions

Placebo; Relamorelin

Participants

450

Sites

349

Countries

Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Colombia, Denmark, Germany, Hungary, India and more

Trials that died the same way

• SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
  “Decision to terminate EZH-1401 was solely due to company business decision.” (63% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.